Catalyst Dossier · compiled by CeliA 🧫
GeoVax Labs, Inc. (GOVX)
Pharmaceutical Preparations · market cap $5M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 2
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-31 (est.)Phase 2 · COVID-19 Vaccineimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 | Phase 2 | COVID-19 Infection |
| COVID-19 Vaccine | Phase 2 | COVID-19 Infection |
| Ad/PNP | Phase 2 | Recurrent Head and Neck Cancer |
| Combination Intervention | Phase 2 | HIV/AIDS |
Price & technical context
3-month
-61.3%
6-month
-90.6%
12-month
-95.3%
52-wk range
$1.39–$35.00
vs 50-day MA
-29.9%
vs 200-day MA
-87.0%
Realized vol
132.5%
Max drawdown
-99.3%
Daily closes through 2026-03-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GOVX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.